Phase 3 ARENSENS clinical trial results were presented at JADPRO 2025, indicating darolutamide plus ADT improved rPFS in prostate cancer.
Prostate and skin cancers are among the most common cancers affecting men. In Advanced Prostate Cancer, lifelong treatment ...
A prostate cancer diagnosis and life during and after treatments can feel overwhelming. Alongside the shock of a diagnosis, ...
The EMA’s assessment confirms the treatment matches the reference drug in quality and performance, potentially expanding ...
WASHINGTON (AP) — Former President Joe Biden is receiving radiation and hormone therapy as part of a new phase of treating the aggressive form of prostate cancer he was diagnosed with after leaving ...
A new form of immunotherapy using innovative nanoparticles can delay resistance to hormone therapy and help men with prostate cancer live longer. Researchers from the University of Sheffield have ...
Dr. Matthew Smith answers the question: 'Hormone Refractory Prostate Cancer?' March 16, 2009 -- Question: What is hormone refractory prostate cancer? Answer: Nearly all men respond to initial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback